PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. - Wikidata - awgldk - TriplyDB

PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly.

PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly.

http://www.wikidata.org/entity/Q44295528

about

Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-alpha/-gamma activator properties NPY neuron-specific Y2 receptors regulate adipose tissue and trabecular bone but not cortical bone homeostasis in mice PPARα-independent actions of omega-3 PUFAs contribute to their beneficial effects on adiposity and glucose homeostasis Differing endoplasmic reticulum stress response to excess lipogenesis versus lipid oversupply in relation to hepatic steatosis and insulin resistance.Oleanolic acid reduces hyperglycemia beyond treatment period with Akt/FoxO1-induced suppression of hepatic gluconeogenesis in type-2 diabetic mice.The power of real-time PCR.A newly identified CG301269 improves lipid and glucose metabolism without body weight gain through activation of peroxisome proliferator-activated receptor alpha and gamma.PPARδ agonists have opposing effects on insulin resistance in high fat-fed rats and mice due to different metabolic responses in muscle.Disparate metabolic response to fructose feeding between different mouse strains High-fat diets: modeling the metabolic disorders of human obesity in rodents.Postburn trauma insulin resistance and fat metabolism.Contrasting metabolic effects of medium- versus long-chain fatty acids in skeletal muscle.Potent anti-diabetic effects of MHY908, a newly synthesized PPAR α/γ dual agonist in db/db mice.Enhancement of muscle mitochondrial oxidative capacity and alterations in insulin action are lipid species dependent: potent tissue-specific effects of medium-chain fatty acids The regulation of glucose metabolism: implications and considerations for the assessment of glucose homeostasis in rodents.Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice.Effects of MHY908, a New Synthetic PPARα/γ Dual Agonist, on Inflammatory Responses and Insulin Resistance in Aged Rats.PPARs and nonalcoholic fatty liver disease.Adrenomedullin in the rostral ventrolateral medulla increases arterial pressure and heart rate: roles of glutamate and nitric oxide.Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease.Carvacrol ameliorates the PPAR-A and cytochrome P450 expression on D-galactosamine induced hepatotoxicity rats.The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats.PPAR-alpha agonism improves whole body and muscle mitochondrial fat oxidation, but does not alter intracellular fat concentrations in burn trauma children in a randomized controlled trial.Ashitaba (Angelica keiskei) extract prevents adiposity in high-fat diet-fed C57BL/6 mice.Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection.Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivo.Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats.Overexpression of APOC1 in obob mice leads to hepatic steatosis and severe hepatic insulin resistance.Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes.[Future targets in the treatment of type 2 diabetes].Antiproliferative effects of calcitonin gene-related peptide in aortic and pulmonary artery smooth muscle cells.Recurrent familial hypobetalipoproteinemia-induced nonalcoholic fatty liver disease after living donor liver transplantation.Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo.PPARα-LXR as a novel metabolostatic signalling axis in skeletal muscle that acts to optimize substrate selection in response to nutrient status.Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.Farnesol, an isoprenoid, improves metabolic abnormalities in mice via both PPARα-dependent and -independent pathways.Trans-species comparison of PPAR and RXR expression by rat and human urothelial tissues.Probucol ameliorates the development of nonalcoholic steatohepatitis in rats fed high-fat diets.Inflammation, dyslipidaemia, diabetes and PPARs: pharmacological interest of dual PPARα and PPARγ agonists

P2860

Q28261771-E340FAA7-B97B-46D8-A76F-244DB593818C Q33627534-EEB255B4-6CD3-4A12-8090-3FEDE511C547 Q33832975-3D1D7CEA-76E0-45F1-BE24-383FB4F5AA1F Q34166238-2AF30E54-5D3F-480F-B172-71B77570F9ED Q34364516-2B2DFB81-537F-4AA3-AD28-E0FD4C3E3F6E Q34444172-C73974D8-5F83-46E0-B3BA-6B45B90C9284 Q34527082-C7CAAAC5-4650-46E2-AA47-E632551BCE3A Q35005682-3E78FF0A-8D95-4636-9726-3C8D93F52374 Q36392668-282523E3-2DB2-4F74-B084-B27089B3AFDB Q36787703-54BF2A31-8D73-45D2-B7D5-C1165B695976 Q36980209-8182DB02-6804-4F34-84D3-572C220990B2 Q37305373-6F648257-519A-43F3-9040-6AE4B0B4854F Q37309163-E926D29A-7999-4043-A1B9-20CCCB51AE4E Q37400725-3DDAE9E1-9E5F-423F-B6F0-4B4A1C1AFDD2 Q38247935-3493A145-037F-434D-A4FC-7FEF581C89A3 Q38325827-5BA4C153-C59C-47A3-8FE5-4C69C494EA7F Q38423900-2C73F3FC-05AD-4EB1-811E-99B3B1430DFE Q39029023-6D4C8781-24BD-40F2-BF73-8523F8EEFA13 Q39858322-CB42541D-C5BF-47C9-9E1E-157F1A0FBE45 Q41457655-F1098175-B297-4109-8740-65947A0E331C Q42015969-76FBCBC4-2B43-488E-BFC2-E06220C286F7 Q42288257-EC876198-38A5-4B34-8231-BE01FEADF55E Q42791366-33ACFDD6-C85B-4AE7-9D82-57C597F8E43A Q42833582-D5FA36E7-9D03-46FD-8BE7-505CAD6F368A Q42997461-B715A426-BA74-42B5-9E99-84D3AC035C2F Q43461615-AFA78E68-1D7B-4FB9-BDA6-E59573F5C18B Q44244722-71B80315-B3C6-4812-B6C1-428DC27B9FE4 Q44605262-8D64DA11-470C-49FE-B2FE-19B6924B529A Q44613028-1F2F2692-0862-4204-88C0-0270A5BE17C7 Q44896352-B507D5E7-DEA8-41E8-B20D-078FD6BC7132 Q44982002-CAD19B7C-05DC-4A53-A9C5-44D3C8B2E37B Q45948449-B3391521-655C-4BBD-9517-12036649FE36 Q46766813-AFC4C083-3748-4B28-A995-6752446F9A30 Q48134225-27D96936-8004-4A3C-B51F-23BF20817137 Q51470916-FA490661-9F38-4407-8E20-3F78D48B83D2 Q53224130-6FC29FAE-2371-42F3-A420-B174F33E99A3 Q53321831-AB522080-42EC-4453-BFEE-85A5CAC043AA Q54297535-078C2038-2D3D-4D13-AC39-74BD0227EED9 Q57244260-4C0A5BB1-7EB4-4DF9-96EC-55BF339A8FE0

P2860

PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly.

http://www.wikidata.org/entity/Q44295528

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

PPARalpha /gamma ragaglitazar ...... n the absence of hepatomegaly.

@en

PPARalpha /gamma ragaglitazar ...... n the absence of hepatomegaly.

@nl

type

label

PPARalpha /gamma ragaglitazar ...... n the absence of hepatomegaly.

@en

PPARalpha /gamma ragaglitazar ...... n the absence of hepatomegaly.

@nl

prefLabel

PPARalpha /gamma ragaglitazar ...... n the absence of hepatomegaly.

@en

PPARalpha /gamma ragaglitazar ...... n the absence of hepatomegaly.

@nl

P1433

Q44295528-F0B81034-2F6D-4CD1-BADD-49F553FF9627

P1476

Q44295528-12690A1E-97F7-4CD1-96CB-7ABD7C0E3198

P2093

Q44295528-0BA3251D-028B-4039-AB86-4F456739DB29

Q44295528-10CF1493-050D-4008-9645-EFD9DE83A960

Q44295528-1332A774-F3EC-424C-A1DC-757A651A351F

Q44295528-152465C5-1296-4B76-B652-7B63C1E3EE4C

Q44295528-30BAD122-833D-4494-8564-EA43053307ED

Q44295528-340A881B-0E3F-4D27-8FDF-B954AF42886E

Q44295528-80A9D981-6B8F-4817-A8A2-05A9B85239A5

Q44295528-843BCB23-C61C-4A88-B630-42514BD6D9E9

Q44295528-B7034D08-A81D-49E3-BF23-A83F97F52FAC

Q44295528-C4571AF2-27D3-4234-86D6-8FE1A2CCFB35

P2860

Q44295528-00FEE23B-70DA-4957-AFFE-C6D4412A6DF1

Q44295528-0E216A44-F08B-4F09-A4BC-00D5E40A429F

Q44295528-1408095E-984D-431D-B8E6-A4F97A58CC56

Q44295528-18699CC2-80B0-4EA1-96A9-58667436DDD7

Q44295528-1C420EEC-AB6E-4062-BC71-0971739E9ADE

Q44295528-1DA8315C-7D62-457B-ACC6-18C5FF51FBEF

Q44295528-1F772F92-02F5-4EAB-BEF4-E11501FE5E85

Q44295528-32A8FB11-4526-445C-A6F6-8B7546FDD03B

Q44295528-40C548F8-9151-4335-8273-1BBF62D43580

Q44295528-46999D23-F5E0-4566-B625-6625A97AF0BC

P304

Q44295528-FF6D2717-4B62-442C-92C1-5603E5AAC002

P31

Q44295528-6EDB97E4-D03D-43E8-87D9-2A38362F6954

P356

Q44295528-19FE6D9E-042D-4FCA-9E46-6EB8FF5A7036

P433

Q44295528-7F71369A-1792-46E3-9F0E-DCD2F3B3314C

P478

Q44295528-18238FCD-B6D9-4BA2-98BA-3ACDCB28B797

P50

Q44295528-5F304E73-830C-45E1-9DE3-3701DEBF2E04

P577

Q44295528-8FB7571D-5F16-4D52-8556-770FB3FBC6D2

P5875

Q44295528-81D26DFC-629B-464C-99EA-E5A81A3A63C6

P698

Q44295528-76738952-94E9-492F-B44C-189C737A9F83

P356

AJPENDO.00299.2002

P1433

American Journal of Physiology - Endocrinology and Metabolism

P1476

PPARalpha /gamma ragaglitazar ...... n the absence of hepatomegaly.

@en

P2093

Bronwyn Ellis

http://www.w3.org/2001/XMLSchema#string

David G Watson

http://www.w3.org/2001/XMLSchema#string

Edward W Kraegen

http://www.w3.org/2001/XMLSchema#string

Gregory J Cooney

http://www.w3.org/2001/XMLSchema#string

Ji-Ming Ye

http://www.w3.org/2001/XMLSchema#string

Karsten Wassermann

http://www.w3.org/2001/XMLSchema#string

Leonie Wood

http://www.w3.org/2001/XMLSchema#string

Per Bo Jensen

http://www.w3.org/2001/XMLSchema#string

Philip Just Larsen

http://www.w3.org/2001/XMLSchema#string

Rikke Veggerby Sørensen

http://www.w3.org/2001/XMLSchema#string

P2860

Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha - and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus

A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION

Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects

The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene

Nonalcoholic Fatty Liver Disease: A Feature of the Metabolic Syndrome

Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight.

Drug treatment of lipid disorders.

P304

E531-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPENDO.00299.2002

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

284

http://www.w3.org/2001/XMLSchema#string

P50

Miguel A Iglesias

P577

2003-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10927758

http://www.w3.org/2001/XMLSchema#string

P698

12556350

http://www.w3.org/2001/XMLSchema#string